DRUG-INDUCED LIVER DISEASE

THIRD EDITION

NEIL KAPLOWITZ MD
Professor of Medicine and Director,
Research Center for Liver Diseases
Chief, Division of GI-Liver, Keck School of Medicine of the
University of Southern California
Los Angeles, CA, USA

LAURIE D. DELEVE MD, PhD
Professor of Medicine
Division of Gastrointestinal and Liver Diseases
Keck School of Medicine of the University of Southern California
Los Angeles, CA, USA
## Contents

Preface to the Third Edition  xiii  
List of Figures  xv  
List of Tables  xix  
List of Contributors  xxiii  

### MECHANISMS OF LIVER INJURY

1. Drug-Induced Liver Injury  
   **NEIL KAPLOWITZ**  
   Introduction 3  
   Clinical Overview 3  
   Pathogenesis 6  
   Diagnosis 9  
   Drug Development 10  
   Postmarketing Monitoring 11  
   Conclusions 12  
   References 13  

2. Cytochrome P450 Activation of Toxins and Hepatotoxicity  
   **F. PETER GUENGERICH**  
   Introduction 15  
   Cytochrome P450 Enzymes 16  
   Contexts of Toxicity 19  
   Bioactivation Reactions 22  
   Strategies for Screening in Drug Development 26  
   The Issue of Human-Specific Metabolites 29  
   Conclusions 29  
   References 30  

3. Mechanistic Role of Acyl Glucuronides  
   **HOWARD HORNG, HILDE SPAHN-LANGGUTH, AND LESLIE Z. BENET**  
   Introduction 35  
   Overview of Major Types of Chemical Reactivities of Acyl Glucuronides 36  
   Biochemical Aspects of Acyl Glucuronidation 38  
   Synthesis, Isolation, and Characterization of Acyl Glucuronides 39  
   Stability of Acyl Glucuronides 44  
   Reversible Binding of Acyl Glucuronides to Proteins 48  
   Covalent Binding of Acyl Glucuronides to Proteins 48  
   Stereochemical Aspects of Acyl Glucuronides 57  
   Predictability of the Covalent Binding of Acidic Drugs 59  

   In Vitro Reactivity Screens Utilizing Nucleophilic Trapping Agents 61  
   Potential Toxicological Significance of the Reactive Acyl Glucuronides 62  
   Acknowledgments 64  
   References 64  

4. Oxidant Stress, Antioxidant Defense, and Liver Injury  
   **MITCHELL R. McGIN AND HARTMUT JAESCHKE**  
   Introduction 71  
   The Major Reactive Oxygen and Nitrogen Species in the Liver and Their Sources 72  
   Pathophysiological Consequences of Oxidative Stress 74  
   Antioxidants 76  
   Drug-Induced Oxidative Stress in the Liver 80  
   References 80  

5. Hepatotoxicity Due to Mitochondrial Injury  
   **JOHN J. LEMASTERS**  
   Introduction 85  
   Overview of Mitochondria 85  
   Mitochondrial Permeability Transition 88  
   Mitochondria and Drug-Induced Hepatic Steatosis 93  
   Conclusions 95  
   Acknowledgments 95  
   References 95  

6. Mechanisms of Cell Death and Relevance to Drug Toxicity  
   **LILY DARA, DERICK HAN, AND NEIL KAPLOWITZ**  
   Introduction 101  
   Classification of Cell Death 102  
   Apoptosis 103  
   Autophagy 106  
   Necrosis: A Programmed Process? 108  
   Cell Death in DILI 110  
   Conclusions 116  
   References 116  

7. Role of Membrane Transport in Hepatotoxicity and Pathogenesis of Drug-Induced Cholestasis  
   **BRUNO STIEGER AND GERD A. KULLAK-ULBRICH**  
   Introduction 123  
   Bile Formation 123  
   Clinical Features of Drug-Induced Cholestasis 124
## CONTENTS

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.</td>
<td>Liver Sinusoidal Endothelial Cells and Liver Injury</td>
<td>135</td>
</tr>
<tr>
<td></td>
<td>Introduction</td>
<td>135</td>
</tr>
<tr>
<td></td>
<td>Liver Sinusoidal Endothelial Cells</td>
<td>136</td>
</tr>
<tr>
<td></td>
<td>Capillarization, Pseudocapillarization, and Drug Metabolism</td>
<td>137</td>
</tr>
<tr>
<td></td>
<td>Liver Sinusoidal Endothelial Cells and Fibrosis</td>
<td>137</td>
</tr>
<tr>
<td></td>
<td>Bone Marrow Liver Sinusoidal Endothelial Progenitor Cells and Liver Regeneration</td>
<td>138</td>
</tr>
<tr>
<td></td>
<td>Manifestations of Liver Sinusoidal Endothelial Cell Injury</td>
<td>138</td>
</tr>
<tr>
<td></td>
<td>Lesions of Heterogeneous Perfusion</td>
<td>138</td>
</tr>
<tr>
<td></td>
<td>Peliosis Hepatis</td>
<td>139</td>
</tr>
<tr>
<td></td>
<td>Sinusoidal Obstruction Syndrome</td>
<td>140</td>
</tr>
<tr>
<td></td>
<td>Acetaminophen</td>
<td>142</td>
</tr>
<tr>
<td></td>
<td>Gemtuzumab Ozogamicin</td>
<td>142</td>
</tr>
<tr>
<td></td>
<td>Oxaliplatin</td>
<td>143</td>
</tr>
<tr>
<td></td>
<td>Conclusions</td>
<td>143</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>143</td>
</tr>
</tbody>
</table>

| 9. | Macrophages and Kupffer Cells in Drug-Induced Liver Injury | 147 |
| | Introduction | 147 |
| | Innate Immune Activation in DILI | 148 |
| | Interactions Between Hepatic Macrophages and Other Cells in the Liver During DILI | 150 |
| | Danger Signals Generated in Drug-Induced Liver Injury and Their Signaling Pathways | 150 |
| | Additional DAMPs/PAMPs Involved in Macrophage Activation in DILI | 151 |
| | Complement and Macrophage Activation | 151 |
| | Diagnosis and Treatment of Drug-Induced Liver Injury: Can Macrophages Be a Target? | 152 |
| | Genetic Susceptibility to DILI | 152 |
| | Conclusions | 153 |
| | References | 153 |

| 10. | Role of Inflammation in Drug-Induced Liver Injury | 157 |
| | Introduction | 157 |
| | Inflammation as a Progression Factor in Idiosyncratic DILI | 159 |
| | Inflammation in Idiosyncratic DILI Responses | 165 |
| | Exogenously Imposed Inflammation as a Susceptibility Factor for Drug-Induced Liver Injury | 166 |
| | Conclusions | 169 |
| | Acknowledgments | 169 |
| | References | 169 |

| 11. | Role of the Adaptive Immune System in Idiosyncratic Drug-Induced Liver Injury | 175 |
| | Introduction | 175 |
| | Clinical Characteristics of IDRS | 176 |
| | Evidence Suggesting that IDILI is Immune Mediated | 177 |
| | Alternative Hypotheses | 180 |
| | Toward a Unifying Hypothesis for IDILI | 182 |
| | Conclusions | 189 |
| | Acknowledgments | 189 |
| | References | 189 |

| 12. | Role of Tissue Repair and Death Proteins in Liver Injury | 195 |
| | Introduction | 195 |
| | Two-Stage Model of Toxicity | 196 |
| | Tissue Repair Follows a Dose Response | 197 |
| | Dose-Responsive Tissue Repair for Mixtures of Hepatotoxicants | 198 |
| | Tissue Repair as a Determinant of the Final Outcome of Toxicity | 198 |
| | Relationship Between Higher Initiation of Liver Injury and Tissue Repair | 200 |
| | Factors Affecting Tissue Repair | 201 |
| | Progression of Liver Injury | 204 |
| | Regression of Injury | 207 |
| | Significance of Tissue Repair | 209 |
| | Significance of Death Proteins in the Spread of Liver Injury | 209 |
| | Conclusions | 209 |
| | References | 210 |

| | Introduction | 215 |
| | Methods and Approaches Used to Identify Genetic Factors in DILI | 216 |
| | Genetic Factors Predicting DILI Susceptibility | 216 |
| | Conclusions | 222 |
| | References | 222 |

## II

### DIAGNOSIS AND MANAGEMENT

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.</td>
<td>Clinical Manifestations and Management of Drug-Induced Liver Diseases</td>
<td>229</td>
</tr>
<tr>
<td></td>
<td>Introduction</td>
<td>229</td>
</tr>
<tr>
<td></td>
<td>Susceptibility Factors: Drug-Induced Liver Injury</td>
<td>230</td>
</tr>
</tbody>
</table>
Clinical Recognition of a Suspected or Probable DILI 231
Clinical and Laboratory Manifestations 231
Manifestations of DILI 232
Nonspecificity of Clinical and Laboratory Manifestations of DILI 232
Signals of Severe Drug-Induced Liver Injury: The Importance of Hy's Law 233
The Important Issue of Drug-Induced Autoimmune Hepatitis 234
Drugs of Special Interest 234
Management and Treatment of DILD 238
Rechallenge 238
References 238

15. Histopathological Evaluation of Drug-Induced Liver Disease 241
DAVID E. KLEINER
Introduction 241
Role of Pathological Evaluation in DILD 242
Patterns of Injury in DILD 242
Using Liver Biopsy to Evaluate DILD 258
Conclusions 260
Acknowledgments 261
References 261

16. Risk Factors for Drug-Induced Liver Disease 265
RAJ VUPPALANCHI AND NAGA CHALASANI
Introduction 265
Host-Related Risk Factors 266
Environmental Risk Factors 269
Compound-Related Risk Factors 269
Conclusions 271
Acknowledgments 271
References 272

17. Biomarkers for Drug-Induced Liver Injury 275
PAUL B. WATKINS
Introduction 275
Current Status of Hepatocellular DILI Biomarkers 276
The Road to Better DILI Biomarkers 277
Metabonomics 278
Transcriptomics 279
Proteomics 280
Example of an Application of Novel Biomarkers to a Clinical Trial: Heparins 282
Serum Protein Adducts 282
Anti-Liver Antibodies 283
Lymphocyte Transformation Test 283
Conclusions 283
References 283

18. Causality Assessment 287
M. ISABEL LUCENA, CAMILLA STEPHENS, MIREN GARCIA-CORTES, AND RAUL J. ANDRADE
Introduction 287
Diagnosis in the Clinical Setting 288
Minimal Elements for Drug-Induced Liver Injury Diagnosis and Publishing 294
Causality Assessment 295
Conclusions 299
References 301

III
HEPATOTOXICITY OF SPECIFIC DRUGS

19. Mechanisms of Acetaminophen-Induced Liver Disease 305
JACK A. HINSON
Introduction 305
Reactive Metabolite Formation 306
Protein Covalent Binding 307
Toxicity Occurs in Two Phases 310
Alterations in Calcium Metabolism 310
Oxidative Stress and Toxicity 311
Mitochondrial Permeability Transition 313
Antioxidant Defense Mechanisms 315
Cell Signaling and Mitochondrial Permeability Transition 317
Hepatic Inflammation 318
Genomics, Proteomics, and Metabolomics 321
Conclusions 321
Acknowledgments 322
References 322

20. Acetaminophen 331
LAURA P. JAMES
Introduction 331
Pharmacology of Acetaminophen 332
Availability of Acetaminophen and Considerations on Regulation 332
Clinical Presentation of Acetaminophen Toxicity 333
Definitions of Toxicity 334
Biomarkers of Toxicity 335
Patient Variability and Acetaminophen Toxicity 335
Acknowledgments 338
References 339
21. Mechanisms Underlying the Hepatotoxicity of Nonsteroidal Antiinflammatory Drugs 343
URS A. BOELSTERLI

NSAID Hepatotoxicity: A Paradigm of IDILI 344
Toxicokinetic Determinants of NSAID Hepatotoxicity: Disposition and Metabolism 345
Toxicodynamic Determinants of NSAID Hepatotoxicity: Cellular and Molecular Mechanisms 351
Patient-Specific Determinants of Susceptibility to NSAID Hepatotoxicity 359
Conclusions 360
References 361

22. Nonsteroidal Antiinflammatory Drugs and Leukotriene Receptor Antagonists 369
JAMES H. LEWIS AND JONATHAN G. STINE

Introduction 370
Incidence of NSAID-Induced Hepatic Injury 370
Effect of Rheumatic Diseases on the Liver 372
Clinical and Biochemical Spectrum of NSAID-Induced Hepatic Injury 372
Hepatic Injury Due to Individual NSAIDs 377
Hepatic Injury Due to DMARDs 388
Hepatotoxicity of Leukotriene Receptor Antagonists 389
Hepatotoxicity of Agents Used in the Treatment of Gout 390
Monitoring for NSAID and Other Antiinflammatory Drug-Induced Hepatic Injury 391
References 393

23. Mechanism, Pathology, and Clinical Presentation of Hepatotoxicity of Anesthetic Agents 403
J. GERALD KENNA

Introduction 403
Clinical Features of Volatile Anesthetic-Induced Hepatotoxicity 404
Metabolism of Volatile Anesthetics 406
Adaptive Immune Responses in Patients with Anesthetic-Induced Liver Injury 408
Animal Models 412
Hydrochlorofluorocarbon Refrigerants 415
Mechanism of Volatile Anesthetic-Induced Liver Injury and Basis of Individual Susceptibility 415
Conclusions 417
References 417

24. Anticonvulsant Agents 423
MUNIR PIRMOHAMED AND J. STEVEN LEEDER

Introduction 423
Carbamazepine 424
Oxcarbazepine 427
Phenytoin 428
Phenobarbital 430
Valproic Acid 430
Felbamate 435
Lamotrigine 435
Management 436
References 437

25. Hepatotoxicity of Psychotropic Drugs and Drugs of Abuse 443
DOMINIQUE LARREY AND MARIE-Pierre RIPault

Introduction 444
Epidemiological Aspects of Psychotropic Hepatotoxicity 444
Identification of Drug-Induced Liver Injury Caused by Psychotropic Agents 445
Factors that Contribute to the Hepatotoxicity of Psychotropic Agents 446
Antidepressants 447
Neuroleptic Agents 452
Anxiolytic Agents 455
Psychostimulating Agents 455
Thymoregulating Agents 455
Herbal Medicines 455
Illegal and Recreational Compounds 456
Conclusions 457
References 457

26. Hepatotoxicity of Antimicrobials and Antifungal Agents 463
RICHARD H. MOSELEY

Introduction 463
Antibacterial Agents 464
Antifungal Agents 470
Conclusions 473
References 473

27. Hepatotoxicity of Antitubercular Drugs 483
SUMITA VERMA AND NEIL KAPLOWITZ

Introduction 483
Incidence of Hepatotoxicity 485
Mechanism of Hepatotoxicity 486
Hepatotoxicity of Individual Drugs 488
Hepatotoxicity with Multidrug Antitubercular Therapy 489
Risk Factors for Antitubercular Therapy Hepatotoxicity 490
Clinical, Biochemical, and Histological Features 494
Management, Including Referral for Liver Transplant 495
Alternative Therapy for Underlying Tuberculosis and Reintroduction of Antitubercular Therapy 496
Antitubercular Therapy in Patients with Underlying Liver Disease 497
Hepatotoxicity of Antitubercular Therapy in Liver Transplant Recipients 497
Recommendations for Monitoring Patients While on ATT 498
Conclusions 499
References 500

28. Hepatotoxicity of Antiviral Agents 505
MARINA NÚÑEZ

Introduction 505
Antiretroviral Drugs 506